Table 1. Treatment History of Relapse... | American Society of Hematology

Table 1.

Treatment History of Relapse APL Cases

Case No.^-150	Induction				Consolidation	Maintenance		Relapse
Case No.^-150	Rx Type	Rx Result	Days RA	Cycles DA	Cycles DA	Proto Arm	Days RA	Days Post-CR	Days Post-RA	Days RA
1	DA	CR	0	1	2	Obs	0	541	—	0
2	DA	CR	0	1	2	Obs	0	266	—	0
3	DA	CR	0	1	2	Obs	0	542	—	0
4	DA	CR	0	1	2	Obs	0	203	—	0
5	DA	CR	0	1	2	Obs	0	124	—	0
6	(RA)DA^-151	CR	0	1	2	Obs	0	488	—	0
7	DA	CR	0	1	1	—	—	119	—	0
8	DA	CR	0	2	—	—	—	47	—	0
9	DA	CR	0	1	2	RA	142	258	0	142
10	DA	CR	0	1	2	RA	365	566	90	365
11	DA	CR	0	1	2	RA	365	821	344	365
12	DA-RA(OP)	1°Res-CR^-152	82	1	0	RA(OP)	99	128	30	181^-153
13	RA	CR	42	0	2	Obs	0	334	334	42
14	RA	CR	52	0	2	(RA)Obs^-155	0	188	174	52
15	RA-DA	1°Res-CR¶	44	1	2	Obs	0	522	540	44
16	RA-DA(OP)	Dc-CR#	19	1	2	—	0	348	410	19
17	RA	CR	50	0	2	RA	365	563	49	415
18	RA	CR	73	0	2	RA	97	202	0	275
19	RA	Tox/CR^-160	23	0	0	—	—	192	189	23
20	RA(OP)^-164	CR	39	0	0	RA(OP)^-164	312	324	0	351^-153

Case No.^-150	Induction				Consolidation	Maintenance		Relapse
Case No.^-150	Rx Type	Rx Result	Days RA	Cycles DA	Cycles DA	Proto Arm	Days RA	Days Post-CR	Days Post-RA	Days RA
1	DA	CR	0	1	2	Obs	0	541	—	0
2	DA	CR	0	1	2	Obs	0	266	—	0
3	DA	CR	0	1	2	Obs	0	542	—	0
4	DA	CR	0	1	2	Obs	0	203	—	0
5	DA	CR	0	1	2	Obs	0	124	—	0
6	(RA)DA^-151	CR	0	1	2	Obs	0	488	—	0
7	DA	CR	0	1	1	—	—	119	—	0
8	DA	CR	0	2	—	—	—	47	—	0
9	DA	CR	0	1	2	RA	142	258	0	142
10	DA	CR	0	1	2	RA	365	566	90	365
11	DA	CR	0	1	2	RA	365	821	344	365
12	DA-RA(OP)	1°Res-CR^-152	82	1	0	RA(OP)	99	128	30	181^-153
13	RA	CR	42	0	2	Obs	0	334	334	42
14	RA	CR	52	0	2	(RA)Obs^-155	0	188	174	52
15	RA-DA	1°Res-CR¶	44	1	2	Obs	0	522	540	44
16	RA-DA(OP)	Dc-CR#	19	1	2	—	0	348	410	19
17	RA	CR	50	0	2	RA	365	563	49	415
18	RA	CR	73	0	2	RA	97	202	0	275
19	RA	Tox/CR^-160	23	0	0	—	—	192	189	23
20	RA(OP)^-164	CR	39	0	0	RA(OP)^-164	312	324	0	351^-153

Abbreviations: Rx, treatment; Proto, protocol; DA, daunorubicin-cytarabine; CR, complete remission; RA, all-transretinoic acid; 1°Res, primary resistance; OP, off protocol; Obs, observation; Dc, discontinued; Tox, toxicity.

F0-150

Cases no. 1 through 19 were previously untreated as required by protocol E2491/INT0129; case no. 20 was a non-protocol case who had been treated with 6 cycles of doxorubicin (60 mg/m²) and cyclophosphamide (600 mg/m²) for breast cancer 2 years before developing APL.

F0-151

Case no. 6 was randomized to RA but did not receive it because we were unable to reduce the WBC count to less than 10,000/μL using hydroxyurea per protocol; the patient then received protocol-specified cross-over DA.

F0-152

Case no. 12 developed prolonged marrow hypoplasia after 1 course of induction chemotherapy and was subsequently treated off-protocol with RA (45 mg/m²/d).

F0-153

After relapse from RA-induced CRs, cases no. 12 and 20 were treated with intravenous liposomal RA (90 mg/m² every other day) for 72 and 15 days, respectively, without clinical response.

F0-155

Case no. 14 was re-randomized per protocol to receive RA maintenance therapy but refused further RA therapy.

¶Case no. 15 failed to achieve CR after 42 days of RA therapy, also complicated by acute thyroiditis, at which time the patient was crossed-over per protocol to DA and achieved CR.

#Case no. 16 developed cerebral aspergillosis after 19 days of protocol RA therapy, requiring discontinuance of this therapy; a subsequent CR was obtained off-protocol by DA.

F0-160

Case no. 19 achieved CR after 20 days of RA therapy but concomitantly developed acute renal failure, after which all further therapy was suspended until clinical relapse.

F0-164

Case no. 20 with secondary APL and doxorubicin-associated cardiomyopathy was treated with continuous RA therapy (45 mg/m²/d) until relapse.

View Large

This Feature Is Available To Subscribers Only